Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Neoadjuvant Muzastotug (ADG126) in Colorectal cancer , Cancer. The expected timing is based on the latest available company guidance and may change.
IIT Trial. 3/24/25- Begin enrolling participants in April 2025 and provide initial clinical data in 2025. 01/23/26:- Preliminary Phase 2 neoadjuvant data, including pathological responses, targeted during 2026. 04/01/26:- Plan to provide preliminary neoadjuvant muzastotug+pembrolizumab Phase 2 colorectal data, including pathological responses, during 2026. 08/12/26:- Investigator-initiated neoadjuvant Ph2 trial remains ongoing. Preliminary clinical data will inform future development.
Verification
Confirm timing and program details against the company announcement or filing.